The cost-effectiveness of personalized genetic medicine: The case of genetic testing in neonatal diabetes

Diabetes Care

Volumn 34, Issue 3, 2011, Pages 622-627

  Greeley, Siri Atma W ^a   John, Priya M ^a   Winn, Aaron N ^b   Ornelas, Joseph ^a   Lipton, Rebecca B ^a   Philipson, Louis H ^a   Bell, Graeme I ^a   Huang, Elbert S ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; INSULIN GLARGINE; SULFONYLUREA;

ADOLESCENT; ARTICLE; CHILD; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; ECONOMIC EVALUATION; FOLLOW UP; GENETIC SCREENING; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; NEWBORN; NEWBORN DISEASE; OUTCOME ASSESSMENT; PERSONALIZED MEDICINE; PREVALENCE; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SENSITIVITY AND SPECIFICITY; SIMULATION;

COST-BENEFIT ANALYSIS; DIABETES MELLITUS; GENETIC TESTING; HUMANS; INFANT; INFANT, NEWBORN;

EID: 79956111232     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc10-1616     Document Type: Article

References (25)

1. Greeley SA, Tucker SE, Naylor RN, Bell GI, Philipson LH. Neonatal diabetes mellitus: a model for personalized medicine. Trends Endocrinol Metab 2010;21:464-472
2. Grulich-Henn J, Wagner V, Thon A, et al. Entities and frequency of neonatal diabetes: data from the diabetes documentation and quality management system (DPV). Diabet Med 2010;27:709-712
3. Gloyn AL, Pearson ER, Antcliff JF, et al. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med 2004;350:1838-1849 (Pubitemid 38917250)
4. Babenko AP, Polak M, Cavé H, et al. Activating mutations in the ABCC8 gene in neonatal diabetes mellitus. N Engl J Med 2006;355:456-466 (Pubitemid 44162273)
5. Støy J, Edghill EL, Flanagan SE, et al.; Neonatal Diabetes International Collaborative Group. Insulin gene mutations as a cause of permanent neonatal diabetes. Proc Natl Acad Sci USA 2007;104:15040-15044
6. Edghill EL, Flanagan SE, Patch AM, et al.; Neonatal Diabetes International Collaborative Group. Insulin mutation screening in 1,044 patients with diabetes: mutations in the INS gene are a common cause of neonatal diabetes but a rare cause of diabetes diagnosed in childhood or adulthood. Diabetes 2008;57:1034-1042
7. Pearson ER, Flechtner I, Njølstad PR, et al.; Neonatal Diabetes International Collaborative Group. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med 2006;355:467-477
8. Støy J, Greeley SA, Paz VP, et al.; United States Neonatal Diabetes Working Group. Diagnosis and treatment of neonatal diabetes: a United States experience. Pediatr Diabetes 2008;9:450-459
9. Mohamadi A, Clark LM, Lipkin PH, Mahone EM, Wodka EL, Plotnick LP. Medical and developmental impact of transition from subcutaneous insulin to oral glyburide in a 15-yr-old boy with neonatal diabetes mellitus and intermediate DEND syndrome: extending the age of KCNJ11 mutation testing in neonatal DM. Pediatr Diabetes 2010;11:203-207
10. Sperling MA. ATP-sensitive potassium channels - neonatal diabetes mellitus and beyond. N Engl JMed 2006;355:507-510 (Pubitemid 44162279)
11. Eckman MH, Rosand J, Greenberg SM, Gage BF. Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann Intern Med 2009;150:73-83
12. Rafiq M, Flanagan SE, Patch AM, Shields BM, Ellard S, Hattersley AT; Neonatal Diabetes International Collaborative Group. Effective treatment with oral sulfonylureas in patients with diabetes due to sulfonylurea receptor 1 (SUR1)mutations. Diabetes Care 2008;31:204-209
13. Girard CA, Wunderlich FT, Shimomura K, et al. Expression of an activating mutation in the gene encoding the KATP channel subunit Kir6.2 in mouse pancreatic beta cells recapitulates neonatal diabetes. J Clin Invest 2009;119:80-90
14. The Diabetes Control and Complications Trial Research Group. Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial. JAMA 1996;276:1409-1415
15. CDC Diabetes Cost-effectiveness Group. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA 2002;287:2542-2551
16. Gray A, Raikou M, McGuire A, et al.; United Kingdom Prospective Diabetes Study Group. Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). BMJ 2000;320:1373-1378
17. Coffey JT, Brandle M, Zhou H, et al. Valuing health-related quality of life in diabetes. Diabetes Care 2002;25:2238-2243 (Pubitemid 41071034)
18. Chin MH, Drum ML, Jin L, Shook ME, Huang ES, Meltzer DO. Variation in treatment preferences and care goals among older patients with diabetes and their physicians. Med Care 2008;46:275-286
19. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB Panel on Cost-effectiveness in Health and Medicine. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 1996;276:1253-1258 (Pubitemid 26337709)
20. Huang ES, Zhang Q, Brown SE, Drum ML, Meltzer DO, Chin MH. The cost-effectiveness of improving diabetes care in U.S. federally qualified community health centers. Health Serv Res 2007;42:2174-2193; discussion 2294-2323
21. Schimmel U. Long-standing sulfonylurea therapy after pubertal relapse of neonatal diabetes in a case of uniparental paternal isodisomy of chromosome 6. Diabetes Care 2009;32:e9
22. Fajans SS, Bell GI, Polonsky KS.Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. N Engl J Med 2001;345:971-980
23. Shepherd M, Shields B, Ellard S, Rubio-Cabezas O, Hattersley AT. A genetic diagnosis of HNF1A diabetes alters treatment and improves glycaemic control in the majority of insulin-treated patients. Diabet Med 2009;26:437-441
24. Eide SA, Raeder H, Johansson S, et al. Prevalence of HNF1A (MODY3) mutations in a Norwegian population (the HUNT2 Study). Diabet Med 2008;25:775-781
25. Rogowski WH, Grosse SD, Khoury MJ. Challenges of translating genetic tests into clinical and public health practice. Nat Rev Genet 2009;10:489-495